ANAB
AnaptysBio Inc
51.00$
-1.4%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Cash Flow
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | -166.2% | – | – | – | – | – | – | – | – | – | – | |
| – | -46.9% | -11.0% | -15.0% | -21.5% | +72.1% | +63.2% | +8.8% | +273.9% | +11.7% | +1.8% | +0.9% | +1.1% | |
| – | +6.0% | +277.5% | +92.1% | +277.4% | +127.5% | +24.6% | -7.3% | +33.5% | +78.2% | +21.4% | +2.5% | +5.9% | |
| – | – | +33.4% | +1.4% | +215.2% | -109.2% | – | +1,673.1% | -83.8% | +857.3% | – | – | – | |
| – | – | -170.5% | – | – | -15.1% | +386.9% | -140.2% | – | – | -104.7% | – | – | |
| – | +291.9% | +64.1% | -79.0% | +480.0% | +266.6% | -24.3% | -29.3% | +140.1% | -73.8% | +125.4% | -55.6% | -75.7% | |
| – | +278.4% | +70.0% | -79.0% | +486,016.0% | -41.4% | – | -28.1% | -58.9% | -1,116.7% | – | -34.1% | +139.0% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +25,430.0% | -100.0% | – | -21.7% | -98.7% | -83.5% | +414.7% | +363.3% | -522.8% | -99.1% | +14,949.6% | |
| – | – | +100.0% | +0.0% | -168.8% | +0.0% | +9.1% | -81.7% | -100.0% | – | – | – | – | |
| – | +150.3% | +701.7% | -78.1% | +3,289.6% | -23.6% | -102.0% | -80.4% | – | -82.6% | -234.7% | – | -204.4% | |
| – | – | +52.2% | -101.5% | – | +8.2% | +77.2% | +38.3% | +208.7% | -273.1% | – | – | +32.1% | |
| – | – | -168.5% | – | – | – | – | – | – | – | – | – | – |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.